To our knowledge, this is the first study to report the nature and prevalence of post-COVID-19 condition, while correcting for individual symptoms present before COVID-19 and the symptom dynamics in the population without SARS-CoV-2 infection during the pandemic. Further research that distinguishes potential mechanisms driving post-COVID-19-related symptomatology is required.
This past month, we saw the publication of the final, pre-specified analysis of the PROpel study, assessing abiraterone and olaparib in combination. This study was…
The third trial to report in this space was TALAPRO-2. Dr. Aggarwal presented the all-comers cohort from this trial at ASCO-GU this spring with the…
There is a paucity of effective systemic therapy options for patients with advanced, chemotherapy-refractory colorectal cancer. We aimed to evaluate the efficacy and safety of…
The TRANSCEND CLL 004 trial represents the most promising data of CAR T-cell therapy – liso-cel – in chronic lymphocytic leukemia (CLL), a disease where…
Patients with relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma for whom treatment has failed with both Bruton tyrosine kinase (BTK) inhibitor and…
Providing care and treatment for people with suicidal ideas, rather than subjecting them to a criminal process, seems intuitively humane and appropriate. And yet, in…
I am an expert in how to destroy global health initiatives. It is a peculiar fact that I have been an intimate witness to the…
Progress in acute myeloid leukaemia treatment is occurring at an unprecedented pace. The past decade has witnessed an increasingly improved scientific understanding of the underlying…
A recent Editorial1 pointed out that the National Health Service (NHS) in the UK is facing its most crucial moment since its inception due to…
